[1]
|
Mamane, Y., Heylbroeck, C., Genin, P., Algarte, M., Servant, M. J., LePage, C., DeLuca, C., Kwon, H., Lin, R. and Hiscott, J. (1999). Interferon regulatory factors: the next generation. Gene 237, 1–14. doi:10.1016/S0378-1119(99)00262-0
|
[2]
|
Taniguchi, T., Ogasawara, K., Takaoka, A. and Tanaka, N. (2001). IRF family of transcription factors as regulators of host defense. Annual Review of Immunology 19, 623-655. doi:10.1146/annurev.immunol.19.1.623
|
[3]
|
Harada, H., Fujita, T., Miyamoto, M., Kimura, Y., Maruyama, M., Furia, A., Miyata, T. and Taniguchi, T. (1989). Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell 4, 729-39. doi:10.1016/0092-8674(89)90107-4
|
[4]
|
Aziz, F., vanWijnen, A. J., Stein, J. L. and Stein, G. S. (1998). HiNF-D (CDP-cut/CDC2/cyclin A/pRB-complex) influences the timing of IRF-2-dependent cell cycle activation of human histone H4 gene transcription at the G1/S phase transition. J Cell Physiology 3, 453-64. DOI: doi:10.1002/(SICI)1097-4652(199812)177:3<453::AID-JCP8>3.0.CO;2-F
|
[5]
|
Yamamoto, H., Lauphier, M. S., Taniguchi, T. and Harada, H. (1994). The oncogenic transcription factor IRF-2 possess a transcriptional repression and a activation domain. Oncogene 9, 1423-1428. http://www.ncbi.nlm.nih.gov/pubmed/8152803
|
[6]
|
Cohen, L. and Hiscott, J. (1992). Characterization of TH3, an induction-specific protein interacting with the interferon beta promoter. Virology 2, 589-99. http://www.ncbi.nlm.nih.gov/pubmed/1448916
|
[7]
|
Cui, L., Deng, Y., Rong, Y., Lou, W., Mao, Z., Feng, Y., Xie, D. and Jin, D. (2012). IRF-2 is over-expressed in pancreatic cancer and promotes the growth of pancreatic cancer cells. Tumour Biology 1, 247-55. doi:10.1007/s13277-011-0273-3
|
[8]
|
Xi, H., and Blanck, G. (2000). Interferon regulatory fac-tor-2 point mutations in human pancreatic tumors. International J. Cancer 87, 6: 803-8. doi:10.1002/1097-0215(20000915)87:6<803::AID-IJC7>3.0.CO;2-E
|
[9]
|
Doherty, G. M., Boucher, L., Sorenson and K., Lowney, J. (2001). Interferon regulatory factor expression in human breast cancer. Annals Surgery 5, 623-9. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1421301/
|
[10]
|
Wang, Y., Liu, D., Chen, P., Koeffler, H. P., Tong, X. and Xie, D. (2008). Negative feedback regulation of IFN-gamma pathway by IFN regulatory factor 2 in esophageal cancers. Cancer Res. 4, 1136-43.
|
[11]
|
Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989). Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
|
[12]
|
Childs, K.S., and Goodbourn, S. (2003). Identification of novel corepressor molecules for Interferon Regulatory Factor-2. Nucleic Acids Res. 12, 3016-26. doi:10.1093/nar/gkg431
|
[13]
|
Taniguchi, T., Tanaka, N., Ogasawara, K., Taki, S., Sato, M. and Takaoka, A. (2000). Transcription factor IRF-1 and its family members in the regulation of host defense. Cold Spring Harb. Symp. Quant. Biol. 64, 465-72. doi:10.1146/annurev.immunol.19.1.623
|
[14]
|
Masumi, A., Wang, I.M., Lefebvre, B., Yang, X.J., Nakatani, Y. and Ozato, K. (1999). The histone acetylase PCAF is a phorbolester-inducible coactivator of the IRF family that confers enhanced interferon responsiveness. Mol. Cell Biol. 3, 1810-20. http://mcb.asm.org/content/19/3/1810.long
|
[15]
|
Upreti, M. and Rath, P.C. (2005). Expression and DNA binding activity of the recombinant interferon regulatory factor-1 (IRF-1) of mouse. Mol. Biol. Rep. 2, 103-16. doi:10.1007/s11033-004-6940-3
|
[16]
|
Lin, R., Mustafa, A., Nguyen, H., Gewert, D. and Hiscott, J. (1994). Mutational analysis of interferon (IFN) regulatory factors 1 and 2 effects on the induction of IFN-beta gene expression. J. Biol. Chem. 26,17542-9. http://www.jbc.org/content/269/26/17542.
|